Alan Armstrong bought Novo Nordisk A/S (NYSE: NVO)
Alan Armstrong (R-OK), a U.S. Senator, has disclosed 1 trade in Novo Nordisk A/S (NVO) since 2026, a single purchase, worth an estimated $33K in disclosed volume (the midpoint of the dollar ranges members report, not exact amounts).
The trade highlighted here is a purchase: Alan Armstrong bought $15,001 - $50,000 of Novo Nordisk A/S (NYSE: NVO) on March 30, 2026. Since that trade, NVO is up +46.25% against the S&P 500 up +17.36%, an outperformance of +28.88%.
Data updated
Alan Armstrong's NVO trades vs the price
NVO is up +46.25% since Alan Armstrong bought on March 30, 2026, versus +17.36% for the S&P 500.
Performance since this trade
All Alan Armstrong NVO trades
Alan Armstrong & NVO trading FAQ
Is it legal for Alan Armstrong to trade Novo Nordisk A/S (NVO) stock?
Yes. Members of Congress are allowed to trade individual stocks, including Novo Nordisk A/S (NVO), but the STOCK Act of 2012 requires them to publicly disclose each transaction within 45 days. Quantellect tracks those disclosures; this page does not imply the trade was improper.
When did Alan Armstrong buy NVO?
Alan Armstrong disclosed a purchase of $15,001 - $50,000 of Novo Nordisk A/S (NVO) on March 30, 2026, according to public STOCK Act filings.
How has NVO performed since Alan Armstrong's trade?
Since Alan Armstrong bought NVO on March 30, 2026, the stock is up +46.25%, versus +17.36% for the S&P 500 over the same period, an outperformance of +28.88%.
How soon must members of Congress disclose a trade?
Under the STOCK Act, members of Congress must publicly report a covered transaction within 45 days of the trade. Filings can still be delayed, amended, or contain errors.
Where can I see all congressional NVO trades?
Quantellect tracks every disclosed congressional trade in Novo Nordisk A/S (NVO) on the Novo Nordisk A/S congressional trading page, which aggregates filings across all members of Congress.
Alan Armstrong's NVO tradesAll congressional filings for Novo Nordisk A/SAlan Armstrong's full profile
Not investment advice. Congressional trading data is sourced from public STOCK Act disclosures, which are filed with a delay and may contain errors or be revised. Estimated prices and post-trade returns are derived algorithmically from public filings and end-of-day market data and describe historical activity, not a recommendation. Always do your own research and consult a licensed financial advisor before making investment decisions.